CHIR-124

CHIR-124 is an inhibitor of CHK and CHK1 and related targets used in studies of MAPK / ERK Signaling and JAK-STAT Signaling and related signaling programs. It is especially relevant in cancer, cell cycle, and cell signaling models, where defined compound exposure can be linked to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-responsive transcriptional signaling and immune regulation.

By inhibiting CHK and CHK1 and related targets, CHIR-124 can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-responsive transcriptional signaling and immune regulation. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell cycle, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving CHK and CHK1 and related targets
• Pathway perturbation studies connected to MAPK / ERK Signaling and JAK-STAT Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, CHIR-124 is appropriate when a defined chemical perturbant is needed to connect CHK and CHK1 and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell cycle, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.